Allergan CEO opposes fundamental shift in strategy, shares fall
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Allergan (AGN) & Medicines360 Highlight 5-Year Trial Data from Largest On-going IUS Clinical Study
April 30, 2018 8:38 AM EDTAllergan plc (NYSE: AGN) and Medicines360 presented five-year data from their ongoing multi-center U.S.-based pivotal clinical trial investigating its intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, at the American College of Obstetricians and Gynecologists (ACOG) 2018 annual clinical and scientific meeting in Austin, Texas. The abstract presents five-year pregnancy rates (by Pearl Index and life-table analysis) and safety outcomes from the ongoing study. The Pearl Index in the first year, among women who were 1635 years old when they enrolled in the study, was 0.15 (CI: 0.02, 0.55). The cumulative life-table pregnancy rate at 5 years was 0.92 (CI:... More
